Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site

Ayna Alfadhli, Henry McNett, Jacob Eccles, Seyram Tsagli, Colleen Noviello, Rachel Sloan, Claudia Lopez, David H. Peyton, Eric Barklis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The matrix domain (MA) of the HIV-1 precursor Gag (PrGag) protein directs PrGag proteins to assembly sites at the plasma membrane by virtue of its affinity to the phospholipid, phos-phatidylinositol-4,5-bisphosphate (PI(4,5)P2). MA also binds to RNA at a site that overlaps its PI(4,5)P2 site, suggesting that RNA binding may protect MA from associating with inappropriate cellular membranes prior to PrGag delivery to the PM. Based on this, we have developed an assay in which small molecule competitors to MA-RNA binding can be characterized, with the assumption that such compounds might interfere with essential MA functions and help elucidate additional features of MA binding. Following this approach, we have identified four compounds, including three thiadiazolanes, that compete with RNA for MA binding. We also have identified MA residues involved in thiadiazolane binding and found that they overlap the MA PI(4,5)P2 and RNA sites. Cell culture studies demonstrated that thiadiazolanes inhibit HIV-1 replication but are associated with significant levels of toxicity. Nevertheless, these observations provide new insights into MA binding and pave the way for the development of antivirals that target the HIV-1 matrix domain.

Original languageEnglish (US)
Pages (from-to)666-676
Number of pages11
JournalJournal of Biological Chemistry
Volume288
Issue number1
DOIs
StatePublished - Jan 4 2013

Fingerprint

RNA
HIV-1
Binding Sites
Ligands
Proteins
Molecules
gag Gene Products
Protein Precursors
Cell membranes
Cell culture
Antiviral Agents
Toxicity
Assays
Phospholipids
Cell Culture Techniques
Cell Membrane
Membranes

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site. / Alfadhli, Ayna; McNett, Henry; Eccles, Jacob; Tsagli, Seyram; Noviello, Colleen; Sloan, Rachel; Lopez, Claudia; Peyton, David H.; Barklis, Eric.

In: Journal of Biological Chemistry, Vol. 288, No. 1, 04.01.2013, p. 666-676.

Research output: Contribution to journalArticle

Alfadhli, Ayna ; McNett, Henry ; Eccles, Jacob ; Tsagli, Seyram ; Noviello, Colleen ; Sloan, Rachel ; Lopez, Claudia ; Peyton, David H. ; Barklis, Eric. / Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site. In: Journal of Biological Chemistry. 2013 ; Vol. 288, No. 1. pp. 666-676.
@article{f147429a7c76484ba15a75e7c0aac8a4,
title = "Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site",
abstract = "The matrix domain (MA) of the HIV-1 precursor Gag (PrGag) protein directs PrGag proteins to assembly sites at the plasma membrane by virtue of its affinity to the phospholipid, phos-phatidylinositol-4,5-bisphosphate (PI(4,5)P2). MA also binds to RNA at a site that overlaps its PI(4,5)P2 site, suggesting that RNA binding may protect MA from associating with inappropriate cellular membranes prior to PrGag delivery to the PM. Based on this, we have developed an assay in which small molecule competitors to MA-RNA binding can be characterized, with the assumption that such compounds might interfere with essential MA functions and help elucidate additional features of MA binding. Following this approach, we have identified four compounds, including three thiadiazolanes, that compete with RNA for MA binding. We also have identified MA residues involved in thiadiazolane binding and found that they overlap the MA PI(4,5)P2 and RNA sites. Cell culture studies demonstrated that thiadiazolanes inhibit HIV-1 replication but are associated with significant levels of toxicity. Nevertheless, these observations provide new insights into MA binding and pave the way for the development of antivirals that target the HIV-1 matrix domain.",
author = "Ayna Alfadhli and Henry McNett and Jacob Eccles and Seyram Tsagli and Colleen Noviello and Rachel Sloan and Claudia Lopez and Peyton, {David H.} and Eric Barklis",
year = "2013",
month = "1",
day = "4",
doi = "10.1074/jbc.M112.399865",
language = "English (US)",
volume = "288",
pages = "666--676",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site

AU - Alfadhli, Ayna

AU - McNett, Henry

AU - Eccles, Jacob

AU - Tsagli, Seyram

AU - Noviello, Colleen

AU - Sloan, Rachel

AU - Lopez, Claudia

AU - Peyton, David H.

AU - Barklis, Eric

PY - 2013/1/4

Y1 - 2013/1/4

N2 - The matrix domain (MA) of the HIV-1 precursor Gag (PrGag) protein directs PrGag proteins to assembly sites at the plasma membrane by virtue of its affinity to the phospholipid, phos-phatidylinositol-4,5-bisphosphate (PI(4,5)P2). MA also binds to RNA at a site that overlaps its PI(4,5)P2 site, suggesting that RNA binding may protect MA from associating with inappropriate cellular membranes prior to PrGag delivery to the PM. Based on this, we have developed an assay in which small molecule competitors to MA-RNA binding can be characterized, with the assumption that such compounds might interfere with essential MA functions and help elucidate additional features of MA binding. Following this approach, we have identified four compounds, including three thiadiazolanes, that compete with RNA for MA binding. We also have identified MA residues involved in thiadiazolane binding and found that they overlap the MA PI(4,5)P2 and RNA sites. Cell culture studies demonstrated that thiadiazolanes inhibit HIV-1 replication but are associated with significant levels of toxicity. Nevertheless, these observations provide new insights into MA binding and pave the way for the development of antivirals that target the HIV-1 matrix domain.

AB - The matrix domain (MA) of the HIV-1 precursor Gag (PrGag) protein directs PrGag proteins to assembly sites at the plasma membrane by virtue of its affinity to the phospholipid, phos-phatidylinositol-4,5-bisphosphate (PI(4,5)P2). MA also binds to RNA at a site that overlaps its PI(4,5)P2 site, suggesting that RNA binding may protect MA from associating with inappropriate cellular membranes prior to PrGag delivery to the PM. Based on this, we have developed an assay in which small molecule competitors to MA-RNA binding can be characterized, with the assumption that such compounds might interfere with essential MA functions and help elucidate additional features of MA binding. Following this approach, we have identified four compounds, including three thiadiazolanes, that compete with RNA for MA binding. We also have identified MA residues involved in thiadiazolane binding and found that they overlap the MA PI(4,5)P2 and RNA sites. Cell culture studies demonstrated that thiadiazolanes inhibit HIV-1 replication but are associated with significant levels of toxicity. Nevertheless, these observations provide new insights into MA binding and pave the way for the development of antivirals that target the HIV-1 matrix domain.

UR - http://www.scopus.com/inward/record.url?scp=84872078381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872078381&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.399865

DO - 10.1074/jbc.M112.399865

M3 - Article

C2 - 23135280

AN - SCOPUS:84872078381

VL - 288

SP - 666

EP - 676

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 1

ER -